TNG908 in MTAP-deleted solid tumors including soft tissue and bone sarcomas

Safety and tolerability of TNG908 in MTAP-deleted solid tumors including sarcomas

Agents: TNG908
Phase I/II
Status Recruiting
Sponsor Tango Therapeutics

 

Further information on Clinicaltrials.gov.

 

Phase I/II study in solid tumor patients with a specific genetic mutation, a MTAP deletion, including sarcomas (soft tissue and bone sarcomas)

WHO is the trial for?
  • Patients of 18 years or older
  • Patients must have a diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
  • Patients must have received prior standard therapy when applicable
  • Overall health of the patient must be good (ECOG performance score of 0 or 1)

WHAT is the key question that this trial is attempting to answer?

 This trial assesses which is the optimal dosage of TNG908 in solid tumors with MTAP deletion (phase 1 of the study) and if the drug can lead to tumor shrinkage or stablize the disease (phase 2).

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

 This study is currently open for recruitment.

WHERE is the trial available?

 The trial is being conducted in several study centers in the US and in France. For further information please check here: https://clinicaltrials.gov/ct2/show/NCT05275478
Study contact: (US)-(857) 320-4899; email: clinicaltrials@tangotx.com

STUDY DESIGN: What does the study look like?

 This study has two phases: In phase 1 of this trial, the optimal dosage of TNG908 is assessed. In phase 2, this dosage will be given to patients with different kinds of solid tumors including sarcomas in order to see if the drug can stablize the disease or shrink the tumor.

HOW do I get more information?

 Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

CONNECT with other patients on this trial

 If you want to connect with other patients considering or participating in this trial, you can find them here.

SHARE your experience

 You want to share your experience on this trial?
Send us an e-mail to: info@sarcoma-patients.org
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

 Not yet available.

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken